This UK company specialises in supporting the challenges of the in-vitro diagnostic industry for the development of the latest generation of highly specific and sensitive diagnostics assays. It achieves this by producing high quality, authentic antigens. Their production platform is designed to meet the safety benefits of traditional recombinant technology whilst maintaining full authentic antigen structure and function. The company’s unique skills and capabilities are drawn from its early connection with the vaccine industry.Because it is important to minimising ‘lot to lot’ variation and its effect on the reproducibility of IVD tests, with each batch production they always make reference to both previous lots and master seed stock and will reject any batch which falls outside of our strict criteria. Correct protein folding, presentation and glycolysation is maintained with native antigens compared to recombinant alternatives. Consequently, antibodies raised against or detected by them in clinical samples, are much more likely to deliver high specificity and sensitivity. Expected to reach the market value:The UK Company has already developed solutions which delivered real improvements to the performance of IVD’s of a number of big global companies and is looking to form long term relationships with Chinese companies. Typically, these clients may be experiencing problems with Sensitivity or Specificity particularly related to their own individual products.  The manufacturing process starts from initial research through to the highest standards of scale up production with minimum risk and cost to the client.Ideal way of cooperation:Import of custom designed antibodies and antigens by Commercial Agreement Ideal partners:Manufacturers of vaccines, diagnostic kits, other bio-pharmaceuticals and medicines.